In H460 lung cancer cells, the use of the SCD1 inhibitor CVT-11127 significantly decreased cell proliferation, an effect that could be reversed by the addition of exogenous MUFAs (OA, palmitoleic or cis-vaccenic acid) [60,210]. Here, SCD is linked to lung carcinoma.